Time-dose factors in radiotherapy: a review of the human data.
about
Emerging Role of Hypofractionated Radiotherapy with Simultaneous Integrated Boost in Modern Radiotherapy of Breast CancerThe tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordomaToxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factorsExternal beam techniques to boost cervical cancer when brachytherapy is not an option-theories and applicationsRadiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases.Hypofractionated radiotherapy in the treatment of early breast cancer.Radiotherapy treatment of non-melanoma skin cancer: a survey of current UK practice and commentaryHealth-related quality of life in survivors of stage I-II breast cancer: randomized trial of post-operative conventional radiotherapy and hypofractionated tomotherapy.Adjuvant chemotherapy and acute toxicity in hypofractionated radiotherapy for early breast cancerThe impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancersLate-responding normal tissue cells benefit from high-precision radiotherapy with prolonged fraction delivery times via enhanced autophagy.Who benefits from hypofractionated radiation therapy for clinically localized prostate cancer: evidence from meta-analysis.Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.Comparison of Acute and Late Toxicity of Two Regimens of 3- and 5-Week Concomitant Boost Prone IMRT to Standard 6-Week Breast Radiotherapy.Head and neck squamous cell carcinoma: optimizing the therapeutic index.Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma.Gastrointestinal radiation injury: symptoms, risk factors and mechanismsThe UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trialAccelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation.Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trialA new view of radiation-induced cancer: integrating short- and long-term processes. Part II: second cancer risk estimation.Modeling of chronic radiation-induced cystitis in mice.What do we know about the α/β for prostate cancer?Shortened radiation therapy schedules for early-stage breast cancer: a review of hypofractionated whole-breast irradiation and accelerated partial breast irradiation.Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung CancerIs grid therapy useful for all tumors and every grid block design?Comparison between model-predicted tumor oxygenation dynamics and vascular-/flow-related Doppler indices.The use of equivalent radiation dose in the evaluation of late effects after childhood cancer treatment.From cell population models to tumor control probability: including cell cycle effects.Postoperative radiotherapy in DBCG during 30 years. Techniques, indications and clinical radiobiological experience.Predictive value of modelled tumour control probability based on individual measurements of in vitro radiosensitivity and potential doubling time.Quantitative clinical radiobiology.Reducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives.Normal Tissue Complications following Hypofractionated Chest Wall Radiotherapy in Breast Cancer Patients and Their Correlation with Patient, Tumor, and Treatment CharacteristicsA Retrospective Analysis of Toxicity and Efficacy for 2 Hypofractionated Irradiation Schedules Versus a Conventional One for Post-Mastectomy Adjuvant Radiotherapy in Breast Cancer.Evaluation of acute/late toxicity and local recurrence in T1-T2 glottic carcinoma treated with accelerated hypofractionated 3D-conformal external beam radiotherapy (3D-CRT).On the need to compensate for edema-induced dose reductions in preplanned (131)Cs prostate brachytherapy.Investigation of effective decision criteria for multiobjective optimization in IMRT.
P2860
Q26774616-D8C2464C-A429-49B8-A8E1-52B9B4862A2EQ26823489-401E57BF-9633-4B82-9881-BA745F46CEE9Q27301421-CFA3C570-C22E-4DFF-8BDF-B41B70D80EC7Q33275033-B76C8201-E95A-4A9C-91A1-E1F05EA90134Q33646182-D9262E22-2D3B-4C31-9AB7-0486998EAB8CQ33747597-3486E9EB-796A-4E18-B693-047AE8865D89Q33922093-0B87B712-FBC9-459F-ADC8-79678CC9C3A6Q34391739-E8C553DF-3E8D-4315-8C13-20C815924DC7Q34392052-DD1682C3-A6EA-4371-8963-EB2212DAC076Q34457957-F8807E51-5284-49CA-B1A0-D69D1DC99980Q34520010-B2713D0C-74AF-41A4-B6B9-AE64C6A91D44Q35158273-9AFF0D8F-A95D-44FA-940F-D120A860430AQ35171994-10318D1F-0FE2-457E-B193-89B7A7A56AA8Q35201788-332B6F2E-7B8B-455C-816C-6A3E4299B005Q35530488-6FC0EF37-7D87-4B55-B0A1-3D8AA8EE3F9BQ35971197-77333FC7-6EC3-493E-8506-6353AC1C0810Q36185629-48FE4386-EC8F-49EB-9FE9-2107F4FAF1ACQ36510348-9FCFFB59-522E-4766-81A3-6F780922B6E6Q36541173-2A241F49-37AE-49B2-BC31-CE395BF61886Q36571627-04CAF6FA-7B4A-47B2-8987-CCCDB117E9A1Q36644097-F615C635-879C-4C3C-9C42-24766950EB0EQ37128114-C8E3BBEE-2FE2-42C4-B850-C61BC61BE198Q37272805-8F8EE56B-1621-4EB3-B848-98E9605E6B3AQ37646108-88861292-AFD1-4F35-A0B3-3B8A47FCF3C3Q38023478-55FE3C8D-F8A5-45C9-A0E9-BD9824E3348BQ38183438-F7D06BB1-2C4D-4767-86C3-519F3F866229Q38880324-10081AF5-3820-4359-ADBA-0D44D21B1CDCQ38905773-320EE16C-A309-47F8-96E7-67A3A85BB467Q38920784-27A96B70-931D-4F73-8F5D-B45D49D0D572Q39176177-6E376FFA-8A61-4C08-A29D-E9312B37C235Q39655737-ADDC68D7-6C71-4BE3-8B8D-46FE0B659D7DQ40094272-82735088-60CF-4127-97C2-743D6F99F2FDQ40094376-ABF306FE-EAC0-4219-A6A9-64AD2429C259Q40821957-10F76F39-8544-4A0C-9842-92866B086CA8Q41276603-F69ECBD9-7808-4161-9484-91D2379378C0Q41601769-6263B130-CB0F-4FF4-A089-A35FE95E80A3Q41635905-7923EDE0-6BF3-4F3E-B3C3-81B030B76D24Q42001440-74A20E9E-3304-4EC5-8439-615B89064AADQ42034341-177DB62C-EE80-4236-83E3-4C78D259FF5EQ42777593-50BAFAE5-89B7-4CC3-8C3B-35346EB2F8DC
P2860
Time-dose factors in radiotherapy: a review of the human data.
description
1990 nî lūn-bûn
@nan
1990 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Time-dose factors in radiotherapy: a review of the human data.
@ast
Time-dose factors in radiotherapy: a review of the human data.
@en
Time-dose factors in radiotherapy: a review of the human data.
@nl
type
label
Time-dose factors in radiotherapy: a review of the human data.
@ast
Time-dose factors in radiotherapy: a review of the human data.
@en
Time-dose factors in radiotherapy: a review of the human data.
@nl
prefLabel
Time-dose factors in radiotherapy: a review of the human data.
@ast
Time-dose factors in radiotherapy: a review of the human data.
@en
Time-dose factors in radiotherapy: a review of the human data.
@nl
P2093
P1476
Time-dose factors in radiotherapy: a review of the human data
@en
P2093
H D Thames
I Turesson
M Overgaard
W Van den Bogaert
P304
P356
10.1016/0167-8140(90)90149-Q
P577
1990-11-01T00:00:00Z